Performance and Usability of a Self-operated Home OCT systemJudy E. Kim, MD
Out of 347 patients in the NOTAL-OCT V2.5 system performance and usability study, 90% could self-operate the device and capture gradable image of their macula. The study demonstrated that elderly patients with intermediate or advanced AMD can effectively self-operate an OCT and that they would consider using it to self-test at home. Home-based OCT testing has the potential to be an adjunct to in-office standard-of-care management and treatment of retinal vascular diseases.
Comparison Between Retinal Images Captured by a Self-Operated, Home-based Optical Coherence Tomography (OCT) System and Commercial OCT SystemsOren Tomkins-Netzer, MD, PhD & Michael J. Elman, MD
The majority of patients in the study were able to successfully self-operate the NOTAL-OCT V2.5 system and obtain OCT images of their own AMD affected eyes. Images captured using the patient self-operated NOTALOCT V2.5 demonstrated 90% sensitivity and 100% specificity to the technician-administered commercial OCT devices. This user-friendly OCT system designed for at-home, technician-free use has the potential to reach image sensitivity and specificity similar to a commercial OCT, and to support regularly scheduled standard-of-care clinical assessments and treatments by ophthalmic specialists.
Patient Experience Self-Operating an Optical Coherence Tomography (OCT) Device Developed for Home UseMichael J. Elman, MD
The usability study demonstrates that elderly patients with intermediate or advanced AMD can effectively self-operate an OCT and that they would consider using it to self-test at home. This home-based OCT testing has the potential to be an adjunct to in-office standard-of-care management and treatment of retinal vascular diseases such as wet AMD, diabetic macular edema, and diabetic retinopathy.
Real-World Analysis of Injection Frequency Following Wet AMD Diagnosis According to Baseline Visual AcuityJudy E. Kim
Undertreatment is a reality in clinical settings. The IRIS® Registry study demonstrated lower injection frequency in nAMD eyes compared to pivotal clinical trials. Undertreatment was regardless of baseline visual acuity (VA), first eye and/or second eye. The injection frequency was lower for the worst VA group for year 1 and year 2; and was lower in year 2 compared to year 1. Under treatment may result in less visual gain compared to the pivotal trials, and did not differ between the first and the second eyes diagnosed.
The Future of AMD Management will Include Home OCT Monitoring by Our PatientsAnat Loewenstein
Dr. Anat Lowenstein presented positive Notal Vision Home OCT clinical trial data and spectral domain B-scan images, sharing that 94% of elderly patients with AMD self-operated the device after a 2-minute tutorial. Dr. Lowenstein described Home OCT as the future of retina disease management.